TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29110849

Group type: COMPARATOR
Intervention: Afatinib monotherapy (40mg daily)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Afatinib plus cetuximab (afatinib 40mg daily + cetuximab 500mg/m)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Afatinib plus cetuximab for patients who received afatinib monotherapy for ≥12 weeks
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Afatinib plus cetuximab for patients who received afatinib monotherapy for <12 weeks
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Afatinib plus cetuximab for patients with T790M-positive tumors
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Afatinib plus cetuximab for patients with T790M-negative tumors
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Afatinib plus cetuximab
Number of subjects: 73

Group type: COMPARATOR
Intervention: Afatinib monotherapy
Number of subjects: 73
Study: 29110945

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 29111011

Group type: EXPERIMENTAL
Intervention: Natalizumab therapy
Number of subjects: 48
Study: 29112084

Group type: EXPERIMENTAL
Intervention: Feed-related splanchnic oxygenation (SrSO2) monitoring during enteral feeding introduction and full enteral feeding (FEF) achievement.
Number of subjects: 20
Study: 29112329

Group type: EXPERIMENTAL
Intervention: PF-04171327 (fosdagrocorat)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Midazolam alone
Number of subjects: 12
Study: 29112593

Group type: EXPERIMENTAL
Intervention: Typical LPDFs in MRA women
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Typical LPDFs in ARA women
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Atypical LPDFs in ARA women
Number of subjects: 25
Study: 29112634

Group type: EXPERIMENTAL
Intervention: Therapy with sympathomimetic drugs and fluid therapy
Number of subjects: 21

Group type: COMPARATOR
Intervention: Non-responders (NR)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Mean BP target of 65 mmHg
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Baroreflex sensitivity (BRS)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: BP variability, HR variability, and baroreflex trends
Number of subjects: 21
Study: 29112650

Group type: EXPERIMENTAL
Intervention: 1,500-mL intravenous fluid bolus
Number of subjects: 276

Group type: COMPARATOR
Intervention: 500-mL intravenous fluid bolus
Number of subjects: 276

Group type: COMPARATOR
Intervention: Reference group (admission pulse pressure 50 mm Hg or greater)
Number of subjects: 276
Study: 29112672

Group type: EXPERIMENTAL
Intervention: Endocervical curettage (ECC)
Number of subjects: 204
Study: 29112763

Group type: EXPERIMENTAL
Intervention: Suvorexant (40/30 mg, 20/15 mg)
Number of subjects: 1518

Group type: COMPARATOR
Intervention: Zolpidem
Number of subjects: 1518
Study: 29112780

Group type: EXPERIMENTAL
Intervention: Consumption of low-fibre grain products
Number of subjects: 431

Group type: EXPERIMENTAL
Intervention: Intake of vegetable protein
Number of subjects: 431

Group type: EXPERIMENTAL
Intervention: Consumption of sugar-sweetened beverages
Number of subjects: 431

Group type: EXPERIMENTAL
Intervention: Energy intake
Number of subjects: 431

Group type: EXPERIMENTAL
Intervention: Vigorous physical activity
Number of subjects: 431

Group type: EXPERIMENTAL
Intervention: Total physical activity
Number of subjects: 431

Group type: EXPERIMENTAL
Intervention: Moderate physical activity
Number of subjects: 431

Group type: EXPERIMENTAL
Intervention: Moderate to vigorous physical activity
Number of subjects: 431

Group type: EXPERIMENTAL
Intervention: Total sedentary behaviour
Number of subjects: 431
Study: 29113961

Group type: EXPERIMENTAL
Intervention: mMammogram intervention group (n=60)
Number of subjects: 120

Group type: COMPARATOR
Intervention: usual care control group (n=60)
Number of subjects: 120
Study: 29113984

Group type: EXPERIMENTAL
Intervention: Cardiovascular complications
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Coronary heart disease
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vascular disease of the lower limbs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vascular disease of the cerebral vessels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Heart failure
Number of subjects: 0
Study: 29114094

Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 2176

Group type: COMPARATOR
Intervention: Clinical risk algorithm
Number of subjects: 2176
Study: 29115994

Group type: EXPERIMENTAL
Intervention: Venlafaxine (VLX) + O-demethyl-venlafaxine (ODV) concentrations measured after phenotyping visit.
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Low doses of omeprazole, midazolam, dextromethorphan, and fexofenadine administered to assess drug metabolizing enzymes activity.
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Follow-up visits for efficacy, tolerance, and observance assessment.
Number of subjects: 205
Study: 29116022

Group type: EXPERIMENTAL
Intervention: Quality improvement project targeting diabetes prevention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multi-site research implementation studies focusing on cardiovascular risk prevention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Collaborative care to address women Veterans' mental health treatment needs
Number of subjects: 0
Study: 29116031

Group type: EXPERIMENTAL
Intervention: MSC-NTF cells
Number of subjects: 0
Study: 29116050

Group type: EXPERIMENTAL
Intervention: Entecavir (ETV)
Number of subjects: 3408

Group type: COMPARATOR
Intervention: Lamivudine (LAM)
Number of subjects: 3408
Study: 29116972

Group type: EXPERIMENTAL
Intervention: Peak systolic global longitudinal strain (GLS) obtained during intraoperative transesophageal echocardiogram before cardiopulmonary bypass.
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: GLS value
Number of subjects: 275

Group type: COMPARATOR
Intervention: First predictive model without GLS
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: Second predictive model with GLS
Number of subjects: 275
Study: 29117930

Group type: EXPERIMENTAL
Intervention: NMIBC-SI (Patient-Reported Symptom Index)
Number of subjects: 450
Study: 29118225

Group type: EXPERIMENTAL
Intervention: Entrectinib
Number of subjects: 0
Study: 29118984

Group type: EXPERIMENTAL
Intervention: ThermoDox® with ultrasound-mediated hyperthermia
Number of subjects: 0

Group type: COMPARATOR
Intervention: ThermoDox® (Part 1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: ThermoDox® (Part 2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Secondary outcomes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tertiary outcomes
Number of subjects: 0
Study: 29119276

Group type: EXPERIMENTAL
Intervention: Gemcitabine, nab-paclitaxel, and pembrolizumab (GNP)
Number of subjects: 17
Study: 29119917

Group type: EXPERIMENTAL
Intervention: E. coli PNP delivered via recombinant adenoviral vector followed by systemic administration of fludarabine phosphate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: E. coli PNP
Number of subjects: 0
Study: 29121278

Group type: EXPERIMENTAL
Intervention: Frontal alpha-delta EEG pattern (delta power >20 dB, alpha power >10 dB)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Ketamine and less volatile anaesthetic co-administration
Number of subjects: 90

Group type: COMPARATOR
Intervention: Depth-of-anaesthesia indices
Number of subjects: 90
Study: 29121645

Group type: EXPERIMENTAL
Intervention: Dasatinib treatment for a median of nine months
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Dasatinib treatment
Number of subjects: 31
Study: 29121934

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20 mg/day for 12 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (healthy controls)
Number of subjects: 20
Study: 29122619

Group type: EXPERIMENTAL
Intervention: Alisertib (single-agent)
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Alisertib plus paclitaxel
Number of subjects: 207

Group type: COMPARATOR
Intervention: Paclitaxel alone
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Aurora A SNP at codon 57
Number of subjects: 207
Study: 29122844

Group type: EXPERIMENTAL
Intervention: Cardiac Magnetic Resonance Imaging (CMR) risk score
Number of subjects: 1196

Group type: EXPERIMENTAL
Intervention: CMR risk score stratification into low (0/1 point) and high-risk group (≥2 points)
Number of subjects: 1196
Study: 29122932

Group type: EXPERIMENTAL
Intervention: Predefined CAD-score algorithm
Number of subjects: 1675

Group type: EXPERIMENTAL
Intervention: Updated CAD-score algorithm (including acoustic features and clinical risk factors)
Number of subjects: 1675

Group type: EXPERIMENTAL
Intervention: Sound-based detection of CAD
Number of subjects: 1675
Study: 29122992

Group type: EXPERIMENTAL
Intervention: Transfusion-dependent patients with detectable labile plasma iron levels and high transferrin saturation levels
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Transfusion-independent patients with ringed sideroblasts
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Transfusion-dependent patients
Number of subjects: 100
Study: 29123425

Group type: EXPERIMENTAL
Intervention: tolvaptan (60-120 mg/d)
Number of subjects: 135
Study: 29124456

Group type: EXPERIMENTAL
Intervention: Exemestane with low-dose oral cyclophosphamide
Number of subjects: 23
Study: 29124506

Group type: EXPERIMENTAL
Intervention: Heart Rate Variability Biofeedback (HRVB)
Number of subjects: 68

Group type: COMPARATOR
Intervention: EEG alpha biofeedback with relaxing music and relaxed paced breathing (EEG+)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Albuterol after biofeedback sessions
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Budesonide (high-potency inhaled steroid)
Number of subjects: 68
Study: 29124992

Group type: EXPERIMENTAL
Intervention: Ketamine infusion (0.15-mg/kg bolus with continuous infusion at 2 µg/kg/min)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control (saline infusion)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Both groups (Ketamine and Control)
Number of subjects: 64
Study: 29125695

Group type: EXPERIMENTAL
Intervention: Age-adjusted D-dimer combined with clinical pretest probability (PTP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Age-adjusted D-dimer
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Negative D-dimer with unlikely PTP
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Limited CUS
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Extended CUS
Number of subjects: 0
Study: 29126426

Group type: EXPERIMENTAL
Intervention: Immediately loaded implants in the maxilla (six implants each, loaded within 24 hours, definitive restoration after 20-24 weeks)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Immediately loaded implants in the maxilla
Number of subjects: 51
Study: 29126444

Group type: EXPERIMENTAL
Intervention: Easily accessible self-management course for chronic pain
Number of subjects: 21
Study: 29126871

Group type: EXPERIMENTAL
Intervention: Lumacaftor/ivacaftor (full dose)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Lumacaftor/ivacaftor (half dose)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Lumacaftor/ivacaftor (half dose increased to full dose)
Number of subjects: 46
Study: 29127195

Group type: EXPERIMENTAL
Intervention: Microcatheter contrast injection (MCI) prior to stent retriever deployment
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Higher Alberta Stroke Program early CT Score (ASPECTS)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Younger age
Number of subjects: 51
Study: 29128389

Group type: EXPERIMENTAL
Intervention: Initial antibiotic therapy (IAT); mean duration 7.8 days; most patients received monotherapy (72.5%)
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: Initial antibiotic therapy (IAT)
Number of subjects: 408
Study: 29128386

Group type: EXPERIMENTAL
Intervention: Self-expanding biodegradable biliary stents (BDBSs) inserted using endoscopic retrograde cholangiography (ERC)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Self-expanding biodegradable biliary stents (BDBSs)
Number of subjects: 13
Study: 29128828

Group type: EXPERIMENTAL
Intervention: Diprospan (betamethasone dual-acting formulation) administered via single-dose intramuscular injection
Number of subjects: 0
Study: 29128863

Group type: EXPERIMENTAL
Intervention: Takotsubo cardiomyopathy patients
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 37
Study: 29128908

Group type: EXPERIMENTAL
Intervention: cetuximab/TPF followed by chemoradiotherapy
Number of subjects: 50
Study: 29129018

Group type: EXPERIMENTAL
Intervention: BIAsp 30 once daily (OD), with the possibility of stepwise treatment intensification up to BIAsp 30 three times daily (TID)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Insulin glargine OD, with the possibility of stepwise treatment intensification with insulin aspart up to TID
Number of subjects: 0
Study: 29129256

Group type: EXPERIMENTAL
Intervention: Instantaneous wave-free ratio (iFR)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Fractional flow reserve (FFR)
Number of subjects: 50
Study: 29129627

Group type: EXPERIMENTAL
Intervention: ARCHITECT immunoassay for serum AFP measurement
Number of subjects: 530
Study: 29129636

Group type: EXPERIMENTAL
Intervention: Postoperative muscle mRNA expression levels in rectus abdominis (RA)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Postoperative muscle protein expression levels in rectus abdominis (RA)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Postoperative systemic inflammation
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Postoperative glucose tolerance
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Gut permeability
Number of subjects: 15

Group type: COMPARATOR
Intervention: Bacteraemia
Number of subjects: 15
Study: 29130367

Group type: EXPERIMENTAL
Intervention: Dignity Talk question framework
Number of subjects: 74
Study: 29130418

Group type: EXPERIMENTAL
Intervention: Early palliative care intervention
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group (no early palliative care intervention)
Number of subjects: 23
Study: 29131802

Group type: EXPERIMENTAL
Intervention: Absorb bioresorbable vascular scaffolds (BVS)
Number of subjects: 1005
Study: 29132305

Group type: EXPERIMENTAL
Intervention: Xerosis cutis
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Pressure ulcers
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Incontinence associated dermatitis
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Skin tears
Number of subjects: 223
Study: 29132341

Group type: EXPERIMENTAL
Intervention: Sinovial H-L® (hybrid formulation of hyaluronic acid)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Triamcinolone acetonide
Number of subjects: 100
Study: 29132379

Group type: EXPERIMENTAL
Intervention: Somatosensory electrical stimulation (SES)
Number of subjects: 8
Study: 29133316

Group type: EXPERIMENTAL
Intervention: NKR-2 treatment administered three times with a 2-week interval between each administration.
Number of subjects: 7
Study: 29133363

Group type: EXPERIMENTAL
Intervention: Preeclampsia group
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Daytime ABP in preeclampsia group
Number of subjects: 156

Group type: COMPARATOR
Intervention: Daytime ABP in control group
Number of subjects: 156
Study: 29133478

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 51
Study: 29133477

Group type: EXPERIMENTAL
Intervention: Volume method
Number of subjects: 169

Group type: COMPARATOR
Intervention: Dimension method
Number of subjects: 169

Group type: COMPARATOR
Intervention: Area method
Number of subjects: 169
Study: 29133513

Group type: EXPERIMENTAL
Intervention: Bevacizumab (BEV) 10 mg/kg IV every 2 weeks combined with Vorinostat (VOR) 400 mg p.o. daily for 7 days on, 7 days off, in a 28-day cycle
Number of subjects: 40
Study: 29133757

Group type: EXPERIMENTAL
Intervention: CRP
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: IL-6
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: PCT
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: sTREM-1
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: CRP and IL-6
Number of subjects: 20
Study: 29134133

Group type: EXPERIMENTAL
Intervention: Slit lamp-adapted anterior segmental photography
Number of subjects: 438

Group type: EXPERIMENTAL
Intervention: Slit lamp-adapted anterior segmental photography with assistance techniques
Number of subjects: 438
Study: 29134449

Group type: EXPERIMENTAL
Intervention: GFR1p calculated according to Fleming with sampling at 3 hours
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: GFR7p using iohexol clearance with blood sampling at seven time points within 5 hours
Number of subjects: 96
Study: 29134606

Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose (500 or 1000 mg) as intravenous infusions
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose (500 or 1000 mg)
Number of subjects: 140
Study: 29134648

Group type: EXPERIMENTAL
Intervention: Baricitinib (0.1 to 17 mg per day)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Baricitinib (therapeutic doses)
Number of subjects: 18
Study: 29134664

Group type: EXPERIMENTAL
Intervention: Ruxolitinib BID (doses based on platelets count), continuously in 28-day cycles for the first 3 cycles
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Azacytidine 25 mg/m2
Number of subjects: 0
Study: 29134924

Group type: EXPERIMENTAL
Intervention: MultiStem® (HLM051)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 220
Study: 29135575

Group type: EXPERIMENTAL
Intervention: Standard antiretroviral therapy
Number of subjects: 5430
Study: 29135685

Group type: EXPERIMENTAL
Intervention: Contralateral suppression of transient-evoked otoacoustic emissions (TEOAEs) measured in right ears with MOC activation achieved by presenting broadband noise to left ears.
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Contralateral suppression of TEOAEs
Number of subjects: 16
Study: 29136201

Group type: EXPERIMENTAL
Intervention: Selumetinib 75 mg monotherapy
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Selumetinib 25 mg plus docetaxel 60 mg/m2
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Selumetinib 75 mg plus docetaxel 60 mg/m2
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Combination therapy (selumetinib plus docetaxel)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Selumetinib 50 mg monotherapy
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Selumetinib pharmacokinetic profile
Number of subjects: 33
Study: 29136228

Group type: EXPERIMENTAL
Intervention: Opioid prescription
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Pain
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Pain-related diagnoses
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Depression and anxiety
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Stroke
Number of subjects: 327
Study: 29136286

Group type: EXPERIMENTAL
Intervention: Brompheniramine
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Chlorpheniramine
Number of subjects: 72
Study: 29136317

Group type: EXPERIMENTAL
Intervention: Belatacept/sirolimus immunotherapy
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Alemtuzumab induction
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Lymphocyte repopulation
Number of subjects: 20
Study: 29136523

Group type: EXPERIMENTAL
Intervention: Hypnosis sedation (group II)
Number of subjects: 300
Study: 29137560

Group type: EXPERIMENTAL
Intervention: Abstinence-contingent monetary incentives added to cessation treatments (PV only, PV+Q, PV+CBT) for four weeks after a quit attempt.
Number of subjects: 661

Group type: EXPERIMENTAL
Intervention: Prescriber visit and facilitated quitline (PV+Q) with incentives.
Number of subjects: 661

Group type: COMPARATOR
Intervention: Prescriber visit for pharmacotherapy only (PV only).
Number of subjects: 661

Group type: COMPARATOR
Intervention: Prescriber visit and telephone cognitive-behavioral therapy (PV+CBT).
Number of subjects: 661
Study: 29138206

Group type: EXPERIMENTAL
Intervention: ICU survivors receiving standard ICU care
Number of subjects: 12000

Group type: COMPARATOR
Intervention: Control cohort of otherwise seriously ill patients
Number of subjects: 12000
Study: 29138245

Group type: EXPERIMENTAL
Intervention: Diabetic patients (DM) undergoing TAVR
Number of subjects: 47643

Group type: COMPARATOR
Intervention: Non-diabetic patients (Control group)
Number of subjects: 47643
Study: 29138320

Group type: EXPERIMENTAL
Intervention: RTS,S vaccine (recombinant circumsporozoite protein-based vaccine)
Number of subjects: 0
Study: 29138340

Group type: EXPERIMENTAL
Intervention: Chimeric Antigen Receptor-Modified T Cells
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 29138569

Group type: EXPERIMENTAL
Intervention: Fluvoxamine (50-300 mg/day for 90 days)
Number of subjects: 299
Study: 29138761

Group type: EXPERIMENTAL
Intervention: Tumor Microenvironment of Metastasis (TMEM)
Number of subjects: 600
Study: 29138986

Group type: EXPERIMENTAL
Intervention: Secukinumab 10 mg/kg (baseline, weeks 2 and 4) followed by subcutaneous secukinumab 150 mg or 75 mg every 4 weeks (starting from week 8)
Number of subjects: 637

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 637

Group type: EXPERIMENTAL
Intervention: Secukinumab (both dose groups)
Number of subjects: 637

Group type: EXPERIMENTAL
Intervention: Secukinumab
Number of subjects: 637
Study: 29139135

Group type: EXPERIMENTAL
Intervention: Quizartinib 60 mg/d for 7 days (DL1; n=6)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Quizartinib 60 mg/d for 14 days (DL2; n=7)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Quizartinib 40 mg/d for 14 days (DL-1; n=6)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Quizartinib in combination with SOC chemotherapy
Number of subjects: 19
Study: 29140542

Group type: EXPERIMENTAL
Intervention: Preoperative vWF-Ag levels
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: vWF-Ag ≥182% cutoff
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: E-selectin correlation with vWF-Ag
Number of subjects: 95
Study: 29140548

Group type: EXPERIMENTAL
Intervention: SANGUINATE (SG) infusion, 320 mg/kg, three weekly infusions
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: SANGUINATE (SG) infusion
Number of subjects: 5
Study: 29140967

Group type: EXPERIMENTAL
Intervention: Vascular occlusion test (3 min of ischemia and reperfusion) using INVOS
Number of subjects: 0
Study: 29140978

Group type: EXPERIMENTAL
Intervention: 10-item Test of Adherence to Inhalers (TAI)
Number of subjects: 795

Group type: EXPERIMENTAL
Intervention: 8-item Morisky Medication Adherence Scale (MMAS-8)
Number of subjects: 795

Group type: COMPARATOR
Intervention: Comparison of adherence measures (TAI vs MMAS-8)
Number of subjects: 795

Group type: EXPERIMENTAL
Intervention: Adherence levels
Number of subjects: 795